These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29154807)

  • 1. Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.
    Mandour M; Vliegen I; Paeshuyse J; Neyts J
    Antiviral Res; 2018 Jan; 149():150-153. PubMed ID: 29154807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
    Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
    Pomeroy JJ; Drusano GL; Rodriquez JL; Brown AN
    Antiviral Res; 2017 Oct; 146():149-152. PubMed ID: 28882564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance.
    Vliegen I; Paeshuyse J; Zhong W; Neyts J
    Antiviral Res; 2015 Aug; 120():112-21. PubMed ID: 26036224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus.
    Chen M; Xu Y; Li N; Yin P; Zhou Q; Feng S; Wu T; Wei L; Wang H; Fu Y; Li YP
    J Gen Virol; 2021 Dec; 102(12):. PubMed ID: 34949310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Samsonova MG; Samsonov AM; Kolchanov NA; Ivanisenko VA
    Biofizika; 2013; 58(5):758-74. PubMed ID: 25481944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.
    Camus G; Xu S; Han B; Lu J; Dvory-Sobol H; Yu M; Cheng G; Miller MD; Doehle BP; Mo H
    Virology; 2018 Jan; 514():134-141. PubMed ID: 29175627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Courtney-Smith M; Brancale A
    Eur J Med Chem; 2017 Jan; 125():1115-1131. PubMed ID: 27810598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
    Horscroft N; Bellows D; Ansari I; Lai VC; Dempsey S; Liang D; Donis R; Zhong W; Hong Z
    J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
    Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
    Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
    Coelmont L; Kaptein S; Paeshuyse J; Vliegen I; Dumont JM; Vuagniaux G; Neyts J
    Antimicrob Agents Chemother; 2009 Mar; 53(3):967-76. PubMed ID: 19104013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    Bukh J
    J Hepatol; 2016 Oct; 65(1 Suppl):S2-S21. PubMed ID: 27641985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
    Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
    J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of Combinatorial Lentiviral Vectors Expressing Multiple Anti-Hepatitis C Virus shRNAs and Their Validation on a Novel HCV Replicon Double Reporter Cell Line.
    Elbadawy HM; Mohammed Abdul MI; Aljuhani N; Vitiello A; Ciccarese F; Shaker MA; Eltahir HM; Palù G; Di Antonio V; Ghassabian H; Del Vecchio C; Salata C; Franchin E; Ponterio E; Bahashwan S; Thabet K; Abouzied MM; Shehata AM; Parolin C; Calistri A; Alvisi G
    Viruses; 2020 Sep; 12(9):. PubMed ID: 32962117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
    Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.